SCHEMBL5664403

SCHEMBL5664403

CC#COC1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28717082 0.96
SCHEMBL28717080 0.93
SCHEMBL8769957 0.86
SCHEMBL11351205 0.79
SCHEMBL6691635 0.79
SCHEMBL183061 0.76 MEN1 (0.36)
SCHEMBL183480 0.74
SCHEMBL7047958 0.74
SCHEMBL2876489 0.74
SCHEMBL8910390 0.73 MEN1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170926-B1 PROCESS FOR THE PREPARATION OF 17-(3-HYDROXYPROPYL)-17-HYDROXYSTEROIDS BAYER IP GMBH (DE) 2014-07-23 EP disclosed
EP-1359921-A4 METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS NEWBIOTICS INC (US) 2006-09-06 EP disclosed
EP-1359921-A2 METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS NewBiotics, Inc. (US) 2003-11-12 EP disclosed
WO-2002056832-A2 METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS NEWBIOTICS, INC. (US) 2002-07-25 WO disclosed
EP-1200130-A2 METHODS FOR TREATING THERAPY-RESISTANT TUMORS Newbiotics, Inc. (US) 2002-05-02 EP disclosed
EP-1200455-A1 ENZYME CATALYZED THERAPEUTIC ACTIVATION Newbiotics Inc. (US) 2002-05-02 EP disclosed
WO-2001007454-A1 ENZYME CATALYZED THERAPEUTIC ACTIVATION NEWBIOTICS, INC. (US) 2001-02-01 WO disclosed
WO-2001007088-A2 METHODS FOR TREATING THERAPY-RESISTANT TUMORS NEWBIOTICS, INC. (US) 2001-02-01 WO disclosed
US-5693628-A HORMON INHIBITOR, ANTIFERTILITY AGENT AND CONTRACEPTIVES JENAPHARM GMBH (DE) 1997-12-02 US disclosed
US-5318989-A Antitumor and -carcinogenic agents; antibiotics; aglycones of esperamycins and calichemicins and having the same mechanism of bioactivity BRISTOL-MYERS SQUIBB COMPANY (US) 1994-06-07 US disclosed
EP-0538898-A2 Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof Bristol-Myers Squibb Company (US) 1993-04-28 EP disclosed
US-5198560-A Antitumor agents based on esperamicin antibiotics BRISTOL-MYERS SQUIBB COMPANY (US) 1993-03-30 US disclosed
EP-0454146-A1 Cytotoxic bicyclo[7.3.1] tridec-4-ene-2,6-diyne compounds and process for the preparation thereof Bristol-Myers Squibb Company (US) 1991-10-30 EP disclosed
US-4873360-A Process for the preparation of cyclopentanoids and novel intermediates produced thereby BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1989-10-10 US disclosed
US-4784996-A Pyrimidoindoles useful as hypoglycaemics JOHN WYETH & BROTHER LTD. (GB) 1988-11-15 US disclosed
US-4390721-A 3-Endo-protected hydroxyl-tricyclo[3,2,0,02,7 ]heptan-6-ones ALLEN & HANBURYS LIMITED (GB) 1983-06-28 US disclosed
US-4181674-A 5-Endo-protected hydroxyl-bicyclo[2,2,1]-heptan-2-ones and process for preparing same ALLEN & HANBURYS LIMITED (GB) 1980-01-01 US disclosed
US-4134911-A 3-Endo-protected hydroxyl-tricyclo[3,2,0,02,7 ]-heptan-6-ones ALLEN & HANBURYS LIMITED (GB) 1979-01-16 US disclosed
US-3940425-A Process for the production of polyunsaturated compounds BAYER AKTIENGESELLSCHAFT (DT) 1976-02-24 US disclosed